A Phase III, Multicentre, Randomized, Double-blind, Parallel-group Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI) in Patients Hospitalized for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)